Comparison of first-line bevacizumab in combination with mFOLFOX6 or XELOX in metastatic colorectal cancer

Bayoglu I. V. , Yildiz İ. , Varol U., Cokmert S., Kucukzeybek Y., Alacacioglu A., ...Daha Fazla

JOURNAL OF BUON, cilt.20, sa.2, ss.460-467, 2015 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 20 Konu: 2
  • Basım Tarihi: 2015
  • Dergi Adı: JOURNAL OF BUON
  • Sayfa Sayıları: ss.460-467


Purpose: Currently, there are several oxaliplatin combination regimens for first-line therapy of metastatic colorectal cancer (mCRC). In this study, we compared the survival outcomes of mCRC patients treated with bevacizumab in combination with either modified 5-FU/FA/oxaliplatin (rnFOLFOX6) or capecitabine/oxaliplatin (XELOX).